Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis.

Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuhara Y, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ishii H, Yokoba M, Tanaka N, Yamaguchi E, Eda R, Tsuchihashi Y, Morimoto K, Akira M, Terada M, Otsuka J, Ebina M, Kaneko C, Nukiwa T, Krischer JP, Akazawa K, Nakata K.

Am J Respir Crit Care Med. 2010 Jun 15;181(12):1345-54. doi: 10.1164/rccm.200906-0978OC.

2.

Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy.

Tazawa R, Inoue Y, Arai T, Takada T, Kasahara Y, Hojo M, Ohkouchi S, Tsuchihashi Y, Yokoba M, Eda R, Nakayama H, Ishii H, Nei T, Morimoto K, Nasuhara Y, Ebina M, Akira M, Ichiwata T, Tatsumi K, Yamaguchi E, Nakata K.

Chest. 2014 Apr;145(4):729-37. doi: 10.1378/chest.13-0603.

PMID:
24158247
3.

[Effectiveness and safety of inhaled granulocyte-macrophage colony-stimulating factor therapy in idiopathic pulmonary alveolar proteinosis].

Ding J, Xiao Y, Dai J, Miao L, Qiu Y, Chen L, Jiang H, Cai H.

Zhonghua Yi Xue Za Zhi. 2015 Sep 8;95(34):2766-70. Chinese.

PMID:
26711974
4.

Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis.

Ohashi K, Sato A, Takada T, Arai T, Nei T, Kasahara Y, Motoi N, Hojo M, Urano S, Ishii H, Yokoba M, Eda R, Nakayama H, Nasuhara Y, Tsuchihashi Y, Kaneko C, Kanazawa H, Ebina M, Yamaguchi E, Kirchner J, Inoue Y, Nakata K, Tazawa R.

Respir Med. 2012 Feb;106(2):284-93. doi: 10.1016/j.rmed.2011.10.019.

5.

Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis.

Seymour JF, Presneill JJ, Schoch OD, Downie GH, Moore PE, Doyle IR, Vincent JM, Nakata K, Kitamura T, Langton D, Pain MC, Dunn AR.

Am J Respir Crit Care Med. 2001 Feb;163(2):524-31.

PMID:
11179134
6.

Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis.

Wylam ME, Ten R, Prakash UB, Nadrous HF, Clawson ML, Anderson PM.

Eur Respir J. 2006 Mar;27(3):585-93.

7.
8.

Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis.

Seymour JF, Begley CG, Dirksen U, Presneill JJ, Nicola NA, Moore PE, Schoch OD, van Asperen P, Roth B, Burdach S, Dunn AR.

Blood. 1998 Oct 15;92(8):2657-67.

9.

Serum neutralizing capacity of GM-CSF reflects disease severity in a patient with pulmonary alveolar proteinosis successfully treated with inhaled GM-CSF.

Arai T, Hamano E, Inoue Y, Ryushi T, Nukiwa T, Sakatani M, Nakata K.

Respir Med. 2004 Dec;98(12):1227-30.

PMID:
15588045
10.

Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis.

Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ, Stoller JK.

Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1143-8.

PMID:
10764303
11.

An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis.

Venkateshiah SB, Yan TD, Bonfield TL, Thomassen MJ, Meziane M, Czich C, Kavuru MS.

Chest. 2006 Jul;130(1):227-37.

PMID:
16840407
12.

A combination therapy of whole lung lavage and GM-CSF inhalation in pulmonary alveolar proteinosis.

Yamamoto H, Yamaguchi E, Agata H, Kandatsu N, Komatsu T, Kawai S, Baba K, Awaya T, Nishikomori R, Tsurusawa M, Nakata K.

Pediatr Pulmonol. 2008 Aug;43(8):828-30. doi: 10.1002/ppul.20856.

PMID:
18618617
13.

[Response to inhaled granulocyte-macrophage colony-stimulating factor in a patient with alveolar proteinosis].

Rodríguez Portal JA, Rodríguez Becerra E, Sánchez Garrido A.

Arch Bronconeumol. 2009 Mar;45(3):150-2. doi: 10.1016/j.arbres.2008.02.006. Spanish.

14.

Quantitative analysis of longitudinal response to aerosolized granulocyte-macrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolar proteinosis.

Robinson TE, Trapnell BC, Goris ML, Quittell LM, Cornfield DN.

Chest. 2009 Mar;135(3):842-8. doi: 10.1378/chest.08-1317.

PMID:
19265094
15.

[Autoantibody against granulocyte-macrophage colony-stimulating factor and other serum markers in pulmonary alveolar proteinosis].

Xu KF, Chen Y, Guo ZJ, Zhu YJ.

Zhonghua Jie He He Hu Xi Za Zhi. 2004 Dec;27(12):824-8. Chinese.

PMID:
15730782
16.

Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose.

Papiris SA, Tsirigotis P, Kolilekas L, Papadaki G, Papaioannou AI, Triantafillidou C, Papaporfyriou A, Karakatsani A, Kagouridis K, Griese M, Manali ED.

Clin Drug Investig. 2014 Aug;34(8):553-64. doi: 10.1007/s40261-014-0208-z.

PMID:
24890235
17.

Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis.

Uchida K, Nakata K, Carey B, Chalk C, Suzuki T, Sakagami T, Koch DE, Stevens C, Inoue Y, Yamada Y, Trapnell BC.

J Immunol Methods. 2014 Jan 15;402(1-2):57-70. doi: 10.1016/j.jim.2013.11.011.

PMID:
24275678
18.
19.

An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.

Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, Huizar I, Dalrymple H, Karnekar R, Thomassen MJ.

Eur Respir J. 2011 Dec;38(6):1361-7. doi: 10.1183/09031936.00197710.

20.

Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis.

Bonfield TL, Russell D, Burgess S, Malur A, Kavuru MS, Thomassen MJ.

Am J Respir Cell Mol Biol. 2002 Oct;27(4):481-6.

PMID:
12356582
Items per page

Supplemental Content

Support Center